PPARγ ligands such as rosiglitazone and pioglitazone, both thiazolidinediones (TZDs), have been utilized as T2D therapeutics on account of their ability to improve insulin responsiveness and lower hyperglycemia, although clinical complications such as increased risk of bone fractures and bladder cancer have limited their use [8]. Here, PPARG is linked to type 2 diabetes mellitus.